Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole. This w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Furuno, Jon P., Tallman, Gregory B., Noble, Brie N., Bubalo, Joseph S., Forrest, Graeme N., Lewis, James S., Bienvenida, Ana F., Holmes, Courtney A., Weber, Bo R., McGregor, Jessina C.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2018
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153813/
https://ncbi.nlm.nih.gov/pubmed/30012757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00893-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars